Table 4.

Management of patients with ocular inflammation flare-up during the study period

Study period	Number of patients with flare-up of ocular inflammation	Treatment for flare-up
3-6 months	4 (17.4%, n = 23)	3 patients ( n = 23, 13%) – reducing the infliximab infusion interval 1 patient ( n = 23, 4.3%) – boosting infliximab dose 1 patient ( n = 23, 4.3%) with persistent vasculitis – MMF and CSA were substituted for methotrexate and adalimumab
6–12 months	4 (19%, n = 21)	1 patient ( n = 21, 4.8%) with papillitis, vitritis, and retinal vasculitis – received additional intravenous pulse steroids and was switched to cyclophosphamide 2 patients ( n = 21, 9.5%) – received increased dose of infliximab 1 patient ( n = 21, 4.8%) with retinal vasculitis – received increased doses of infliximab along with MMF and CSA
12–18 months	2 (9.5%, n = 21)	1 patient ( n = 21, 4.8%) with persistent retinal vasculitis – received increased dose of infliximab along with oral corticosteroids 1 patients ( n = 21, 4.8%) – relapsed with anterior uveitis and was restarted on infliximab
18–24 months	3 (14.3%, n = 21)	1 patient ( n = 21, 4.8%) – added methotrexate 1 patient ( n = 21, 4.8%) – reducing interval and boosting dose of infliximab 1 patient ( n = 21, 4.8%) – increasing the dose of infliximab with oral steroids
MMF, mycophenolate mofetil; CSA, Cyclosporin-A